Top

Published in:

Open Access 01-12-2015 | Review

The role of IL-33 and mast cells in allergy and inflammation

Authors: Rohit Saluja, Mahejibin Khan, Martin K. Church, Marcus Maurer

Published in: Clinical and Translational Allergy | Issue 1/2015

Abstract

Interleukin-33 (IL-33) is a member of the interleukin-1 (IL-1) cytokine family. It is preferentially and constitutively expressed in different structural cells such as epithelial cells, endothelial cells, and smooth muscle cells. During necrosis of these cells (after tissue injury or cell damage), the IL-33 that is released may be recognized by different types of immune cells, such as eosinophils, basophils and, especially, mast cells. IL-33 needs the specific receptor ST2 (membrane-bound receptor) and Interleukin-1 receptor accessory protein heterodimer for its binding, which instigates the production of different types of cytokines and chemokines that have crucial roles in the exacerbation of allergic diseases and inflammation. IL-33 and mast cells have been influentially associated to the pathophysiology of allergic diseases and inflammation. IL-33 is a crucial regulator of mast cell functions and might be an attractive therapeutic target for the treatment of allergic and inflammatory diseases. In this review, we summarize the current knowledge regarding the roles of IL-33 and mast cells in the pathogenesis of allergies and inflammation.

Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al. Production and functions of IL-33 in the central nervous system. Brain Res. 2011;1385:8–17. doi:10.1016/j.brainres.2011.02.045.CrossRefPubMed

Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10(2):103–10. doi:10.1038/nri2692.CrossRefPubMed

Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22. doi:10.1186/1476-9255-8-22.CrossRef

Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol. 2012;188(7):3488–95. doi:10.4049/jimmunol.1101977.CrossRefPubMed

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479–90. doi:10.1016/j.immuni.2005.09.015.CrossRefPubMed

Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104(1):282–7. doi:10.1073/pnas.0606854104.CrossRefPubMedPubMedCentral

Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS One. 2008;3(10):e3331. doi:10.1371/journal.pone.0003331.CrossRefPubMedPubMedCentral

Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384(1):105–9. doi:10.1016/j.bbrc.2009.04.081.CrossRefPubMed

Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2010;125(3):752–4. doi:10.1016/j.jaci.2009.12.935.CrossRefPubMed

10.

Andronicos NM, McNally J, Kotze AC, Hunt PW, Ingham A. Trichostrongylus colubriformis larvae induce necrosis and release of IL33 from intestinal epithelial cells in vitro: implications for gastrointestinal nematode vaccine design. Int J Parasitol. 2012;42(3):295–304. doi:10.1016/j.ijpara.2012.01.007.CrossRefPubMed

11.

Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol. 2011;12(7):631–8. doi:10.1038/ni.2045.CrossRefPubMedPubMedCentral

12.

Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464(7293):1367–70. doi:10.1038/nature08900.CrossRefPubMedPubMedCentral

13.

Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA. 2010;107(25):11489–94. doi:10.1073/pnas.1003988107.CrossRefPubMedPubMedCentral

14.

Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183(8):5094–103. doi:10.4049/jimmunol.0802387.CrossRefPubMed

15.

Byers DE, Alexander-Brett J, Patel AC, Agapov E, Dang-Vu G, Jin X, et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Investig. 2013;123(9):3967–82. doi:10.1172/JCI65570.CrossRefPubMedPubMedCentral

16.

Arshad MI, Piquet-Pellorce C, L’Helgoualc’h A, Rauch M, Patrat-Delon S, Ezan F, et al. TRAIL but not FasL and TNFalpha, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology. 2012;56(6):2353–62. doi:10.1002/hep.25893.CrossRefPubMed

17.

Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 2014;31:31–7. doi:10.1016/j.coi.2014.09.004.CrossRefPubMed

18.

Kamijo S, Takeda H, Tokura T, Suzuki M, Inui K, Hara M, et al. IL-33-mediated innate response and adaptive immune cells contribute to maximum responses of protease allergen-induced allergic airway inflammation. J Immunol. 2013;190(9):4489–99. doi:10.4049/jimmunol.1201212.PubMed

19.

Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. Immunity. 2014;40(3):425–35. doi:10.1016/j.immuni.2014.01.011.CrossRefPubMedPubMedCentral

20.

Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol. 2011;23(5):307–15. doi:10.1093/intimm/dxr006.CrossRefPubMed

21.

Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage—CD25 + CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol. 2012;188(3):1503–13. doi:10.4049/jimmunol.1102832.CrossRefPubMedPubMedCentral

22.

Haenuki Y, Matsushita K, Futatsugi-Yumikura S, Ishii KJ, Kawagoe T, Imoto Y, et al. A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol. 2012;130(1):184 e11–194 e11. doi:10.1016/j.jaci.2012.02.013.CrossRefPubMed

23.

Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210(13):2939–50. doi:10.1084/jem.20130351.CrossRefPubMedPubMedCentral

24.

Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463(7280):540–4. doi:10.1038/nature08636.CrossRefPubMed

25.

Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011;12(11):1055–62. doi:10.1038/ni.2104.CrossRefPubMed

26.

Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int. 2010;59(2):143–60. doi:10.2332/allergolint.10-RAI-0186.CrossRefPubMed

27.

Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007;13(7):851–6. doi:10.1038/nm1603.CrossRefPubMed

28.

Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021–6. doi:10.1073/pnas.0812690106.CrossRefPubMedPubMedCentral

29.

Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49–77. doi:10.1146/annurev-immunol-032414-112306.CrossRefPubMed

30.

Martin MU. Special aspects of interleukin-33 and the IL-33 receptor complex. Semin Immunol. 2013;25(6):449–57. doi:10.1016/j.smim.2013.10.006.CrossRefPubMed

31.

Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol. 2010;37(1):18–25. doi:10.3899/jrheum.090492.CrossRefPubMed

32.

Le Goffic R, Arshad MI, Rauch M, L’Helgoualc’h A, Delmas B, Piquet-Pellorce C, et al. Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol. 2011;45(6):1125–32. doi:10.1165/rcmb.2010-0516OC.CrossRefPubMed

33.

Kouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. 2011;186(7):4375–87. doi:10.4049/jimmunol.1003020.CrossRefPubMedPubMedCentral

34.

Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity. 2009;31(1):84–98. doi:10.1016/j.immuni.2009.05.007.CrossRefPubMed

35.

Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284(29):19420–6. doi:10.1074/jbc.M901744200.CrossRefPubMedPubMedCentral

36.

Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol. 2009;183(12):7890–7. doi:10.4049/jimmunol.0802449.CrossRefPubMed

37.

Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors—insight into heterotrimeric IL-1 signaling complexes. Structure. 2009;17(10):1398–410. doi:10.1016/j.str.2009.08.009.CrossRefPubMedPubMedCentral

38.

Lefrancais E, Cayrol C. Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members. Eur Cytokine Netw. 2012;23(4):120–7. doi:10.1684/ecn.2012.0320.PubMed

39.

Roy A, Ganesh G, Sippola H, Bolin S, Sawesi O, Dagalv A, et al. Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation. J Biol Chem. 2014;289(1):237–50. doi:10.1074/jbc.M112.435156.CrossRefPubMedPubMedCentral

40.

Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev. 2010;9(8):531–5. doi:10.1016/j.autrev.2009.12.013.CrossRefPubMed

41.

Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. Mucosal Immunol. 2012;5(4):354–66. doi:10.1038/mi.2012.24.CrossRefPubMed

42.

Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179(4):2551–5.CrossRefPubMed

43.

Funakoshi-Tago M, Tago K, Hayakawa M, Tominaga S, Ohshio T, Sonoda Y, et al. TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal. 2008;20(9):1679–86. doi:10.1016/j.cellsig.2008.05.013.CrossRefPubMed

44.

Saluja R, Ketelaar ME, Hawro T, Church MK, Maurer M, Nawijn MC. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol. 2015;63(1):80–5. doi:10.1016/j.molimm.2014.06.018.CrossRefPubMed

45.

Saluja R, Hawro T, Eberle J, Church MK, Maurer M. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J Biol Regul Homeost Agents. 2014;28(4):575–85.PubMed

46.

Enoksson M, Lyberg K, Moller-Westerberg C, Fallon PG, Nilsson G, Lunderius-Andersson C. Mast cells as sensors of cell injury through IL-33 recognition. J Immunol. 2011;186(4):2523–8. doi:10.4049/jimmunol.1003383.CrossRefPubMed

47.

Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5 + T cells and promotes allergic-induced airway inflammation independent of IL-4. Journal of immunology. 2008;181(7):4780–90.CrossRef

48.

Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy. 2012;67(9):1118–26. doi:10.1111/j.1398-9995.2012.02859.x.CrossRefPubMedPubMedCentral

49.

Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87(10):971–8. doi:10.1038/labinvest.3700663.CrossRefPubMed

50.

Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105(31):10913–8. doi:10.1073/pnas.0801898105.CrossRefPubMedPubMedCentral

51.

Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol. 2009;183(6):3591–7. doi:10.4049/jimmunol.0900328.CrossRefPubMed

52.

Cho KA, Suh JW, Sohn JH, Park JW, Lee H, Kang JL, et al. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L429–40. doi:10.1152/ajplung.00252.2011.CrossRefPubMed

53.

Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy. 2002;32(10):1520–6.CrossRefPubMed

54.

Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282(36):26369–80. doi:10.1074/jbc.M704916200.CrossRefPubMed

55.

Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 1999;190(7):895–902.CrossRefPubMedPubMedCentral

56.

Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med. 2009;179(9):772–81. doi:10.1164/rccm.200805-666OC.CrossRefPubMedPubMedCentral

57.

Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386(1):181–5. doi:10.1016/j.bbrc.2009.06.008.CrossRefPubMed

58.

Sjoberg LC, Gregory JA, Dahlen SE, Nilsson GP, Adner M. Interleukin-33 exacerbates allergic bronchoconstriction in the mice via activation of mast cells. Allergy. 2015;70(5):514–21. doi:10.1111/all.12590.CrossRefPubMed

59.

Stolarski B, Kurowska-Stolarska M, Kewin P, Xu D, Liew FY. IL-33 exacerbates eosinophil-mediated airway inflammation. J Immunol. 2010;185(6):3472–80. doi:10.4049/jimmunol.1000730.CrossRefPubMed

60.

Lee HY, Rhee CK, Kang JY, Byun JH, Choi JY, Kim SJ, et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp Lung Res. 2014;40(2):66–76. doi:10.3109/01902148.2013.870261.CrossRefPubMed

61.

Raeiszadeh Jahromi S, Mahesh PA, Jayaraj BS, Madhunapantula SR, Holla AD, Vishweswaraiah S, et al. Serum levels of IL-10, IL-17F and IL-33 in patients with asthma: a case-control study. J Asthma. 2014;51(10):1004–13. doi:10.3109/02770903.2014.938353.CrossRefPubMed

62.

Kaur D, Gomez E, Doe C, Berair R, Woodman L, Saunders R, et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk. Allergy. 2015;70(5):556–67. doi:10.1111/all.12593.CrossRefPubMedPubMedCentral

63.

Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet. 2005;14(19):2919–27. doi:10.1093/hmg/ddi323.CrossRefPubMed

64.

Savinko T, Matikainen S, Saarialho-Kere U, Lehto M, Wang G, Lehtimaki S, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol. 2012;132(5):1392–400. doi:10.1038/jid.2011.446.CrossRefPubMed

65.

Meephansan J, Tsuda H, Komine M, Tominaga S, Ohtsuki M. Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes. J Invest Dermatol. 2012;132(11):2593–600. doi:10.1038/jid.2012.185.CrossRefPubMed

66.

Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA. 2013;110(34):13921–6. doi:10.1073/pnas.1307321110.CrossRefPubMedPubMedCentral

67.

Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol. 2012;132(5):1326–9. doi:10.1038/jid.2012.66.CrossRefPubMedPubMedCentral

68.

Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2011;31(9):2080–9. doi:10.1161/ATVBAHA.111.231431.CrossRefPubMed

69.

Masamune A, Watanabe T, Kikuta K, Satoh K, Kanno A, Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2010;299(4):G821–32. doi:10.1152/ajpgi.00178.2010.CrossRefPubMed

70.

Velickovic M, Pejnovic N, Petrovic R, Mitrovic S, Jeftic I, Kanjevac T, et al. Expression of interleukin-33 and its receptor ST2 in periapical granulomas and radicular cysts. J Oral Pathol Med. 2015;. doi:10.1111/jop.12312.PubMed

71.

Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous (‘idiopathic’) urticaria. Br J Dermatol. 2014;. doi:10.1111/bjd.13621.PubMedCentral

72.

Tong X, Lu F. IL-33/ST2 involves the immunopathology of ocular toxoplasmosis in murine model. Parasitol Res. 2015;114(5):1897–905. doi:10.1007/s00436-015-4377-3.CrossRefPubMed

73.

Tjota MY, Hrusch CL, Blaine KM, Williams JW, Barrett NA, Sperling AI. Signaling through FcRgamma-associated receptors on dendritic cells drives IL-33-dependent TH2-type responses. J Allergy Clin Immunol. 2014;134(3):706 e8–713 e8. doi:10.1016/j.jaci.2014.06.013.CrossRefPubMed

74.

Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82(6):1481–90. doi:10.1189/jlb.0407200.CrossRefPubMed

75.

Andrade MV, Iwaki S, Ropert C, Gazzinelli RT, Cunha-Melo JR, Beaven MA. Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol. 2011;41(3):760–72. doi:10.1002/eji.201040718.CrossRefPubMedPubMedCentral

76.

Yang Z, Sun R, Grinchuk V, Fernandez-Blanco JA, Notari L, Bohl JA, et al. IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. Am J Physiol Gastrointest Liver Physiol. 2013;304(4):G381–9. doi:10.1152/ajpgi.00357.2012.CrossRefPubMedPubMedCentral

77.

Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20(6):791–800. doi:10.1093/intimm/dxn037.CrossRefPubMed

78.

Tung HY, Plunkett B, Huang SK, Zhou Y. Murine mast cells secrete and respond to interleukin-33. J Interferon Cytokine Res. 2014;34(3):141–7. doi:10.1089/jir.2012.0066.CrossRefPubMedPubMedCentral

79.

Matsuda A, Okayama Y, Terai N, Yokoi N, Ebihara N, Tanioka H, et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci. 2009;50(10):4646–52. doi:10.1167/iovs.08-3365.CrossRefPubMed

Title: The role of IL-33 and mast cells in allergy and inflammation
Authors: Rohit Saluja
Mahejibin Khan
Martin K. Church
Marcus Maurer
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Clinical and Translational Allergy / Issue 1/2015
Electronic ISSN: 2045-7022
DOI: https://doi.org/10.1186/s13601-015-0076-5

At a glance: The STEP trials

Springer Medicine

The role of IL-33 and mast cells in allergy and inflammation

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Antigen-induced airway hyperresponsiveness and obstruction is related to caveolin-1 expression in airway smooth muscle in a guinea pig asthma model

Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria

Immunological events in chronic spontaneous urticaria

Mapping hypersensitivity/allergic diseases in the International Classification of Diseases (ICD)-11: cross-linking terms and unmet needs

Cough hypersensitivity as a neuro-immune interaction